2021-approved atogepant drug reduces rebound headaches in chronic migraine patients, study finds.
New study in Neurology reveals that atogepant, a migraine prevention drug, may be effective in reducing rebound headaches caused by overuse of pain medication in people with chronic migraine. The study involved 755 participants, with those taking atogepant twice daily reporting an average of three fewer migraine and headache days per month than the placebo group. Atogepant received U.S. approval in 2021.
June 26, 2024
3 Articles